As provided at the 2012 ASCO annual meeting initially, this was the first prospective study to show a clinical benefit of a targeted therapy for individuals with KRAS-mutant cancers of any type.. Array BioPharma first one fourth 2013 income decreases to $15.8 million Array BioPharma Inc. today reported outcomes for the first one fourth of its fiscal season ending June 30, 2013. Array continues its development into a late-stage advancement company, with five items approaching Stage 3 decisions by the finish of calendar year 2013.8 million for the initial quarter of fiscal 2013, compared to revenue of $22.1 million for the same period in fiscal 2012. The Company recorded expenses of $13.5 million on proprietary advancement and study for the quarter to advance its clinical development and discovery programs, in comparison to $12.6 million through the same period this past year.8 million, or per share, compared to $3.6 million, or per share, for the same period last year.Children and Adults six months to 64 years of age with chronic conditions, including cancers, immunodeficiency, immunosuppression , renal disease, hemoglobinopathy and anaemia. Healthy children six to 23 weeks old. Related StoriesAustralian researchers discover a way to boost cross-protective capabilities of influenza A vaccineAnalyzing potential TB vaccineGHIT Fund invests $10.7 million to fight malaria, TB, leishmaniasis and dengueWhile this purchase meets current demands, it is early in the flu period still.